A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study

Neuropsychopharmacology

Volumn 30, Issue 8, 2005, Pages 1576-1583

  Henry, Michael E ^a   Schmidt, Mark E ^b   Hennen, John ^a   Villafuerte, Rosemond A ^a   Butman, Michelle L ^a   Tran, Pierre ^b   Kerner, Lynn T ^a   Cohen, Bruce ^a   Renshaw, Perry F ^a  

^a MCLEAN HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; Drug development; Enantiomer; Fluorine MRS; Fluoxetine; Pharmacokinetics

Indexed keywords

FLUORINE; FLUOXETINE; NORFLUOXETINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG ELIMINATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; ISOMERISM; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QT INTERVAL; RACEMIZATION;

BRAIN; BRAIN CHEMISTRY; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FLUOXETINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 23844454579     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300749     Document Type: Article

References (28)

1. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM (2003). What clinicians should know about the QT interval. J Am Med Assoc 289: 2120-2127.
2. Beasley Jr CM, Nilsson ME, Koke SC, Gonzales JS (2000). Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. J Clin Psychiatry 61: 722-728.
3. Bergstrom RF, Beasley Jr CM, Levy NB, Blumenfield M, Lemberger L (1993). The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Int Clin Psychopharmacol 8: 261-266.
4. Bergstrom RF, Peyton AL, Lemberger L (1992). Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51: 239-248.
5. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP (2000). Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23: 428-438.
6. Cheer SM, Goa KL (2001). Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 61: 81-110.
7. Christensen JD, Babb SM, Cohen BM, Renshaw PF (1998). Quantitation of dexfenfluramine/d-norfenfruramine concentration in primate brain using 19F NMR spectroscopy. Magn Reson Med 39: 149-154.
8. Christensen JD, Yurgelun-Todd DA, Babb SM, Gruber SA, Cohen BM, Renshaw PF (1999). Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy. Brain Res 834: 1-5.
9. Claasen-Vujcic T, Borsboom HM, Gaykema HJ, Mehlkopf T (1996). Transverse low field RF coils in MRI. Magn Reson Med 36: 111-126.
10. Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM et al (2003). Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 114: 135-141.
11. Eli Lilly and Company (December, 1999). Investigators Brochure, data on file.
12. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E et al (2002). Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolescent Psychiatry 41: 1205-1215.
13. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J et al (2002). Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 22: 379-387.
14. Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E et al (2000). Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 157: 1506-1508.
15. Jannuzzi G, Gatti G, Magni P, Spina E, Pacifici R, Zuccaro P et al (2002). Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit 24: 616-627.
16. Kikinis R, Shenton ME, Gerig G, Martin J, Anderson M, Metcalf D et al (1992). Routine quantitative analysis of brain and cerebrospinal fluid spaces with MR imaging. J Magn Reson Imaging 2: 619-629.
17. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP (2002). R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27: 949-959.
18. McConathy J, Owens MJ (2003). Stereochemistry in drug action. Primary Care Companion J Clin Psychiatry 5: 70-73.
19. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R (2003). Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 3: 292-303.
20. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and β-fluoxetine. Biol Psychiatry 50: 345-350.
21. Robertson DW, Krushinski JH, Fuller RW, Leander JD (1988). Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor. J Med Chem 31: 1412-1417.
22. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R (2002). Treatment approaches to major depressive disorder relapse. Part 1: dose increase. Psychother Psychosom 71: 190-194.
23. Stevens JC, Wrighton SA (1993). Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 266: 964-971.
24. Strauss WL, Unis AS, Cowan C, Dawson G, Dager SR (2002). Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiatry 159: 755-760.
25. Tonini M, Vigneri S, Savarino V, Scarpignato C (2001). Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 33: 600-606.
26. Vandel P (2003). Antidepressant drugs in the elderly-role of the cytochrome P450 2D6. World J Biol Psychiatry 4: 74-80.
27. Wade A, Michael Lemming O, Bang Hedegaard K (2002). Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17: 95-102.
28. Wikell C, Apelqvist G, Carlsson B, Hjorth S, Bergqvist PB, Kugelberg FC et al (1999). Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats. Clin Neuropharmacol 22: 327-336.